Her2 (ERBB2) Antibody [Clone ID: Abz518]

CAT#: TA397401

Recombinant Anti-HER2 Fab Antibody

Product Images

Flow Cytometry of Humanized Recombinant Anti-human HER2 Fab fragment Antibody. Primary Antibody: Recombinant Anti-HER2 Fab fragment (red line) recognizes HER2 on SK-OV-3 cells while using Anti-human kappa FITC secondary antibody at 0.2 µL with a 56.8% positive cells. Controls used: (black line) no primary antibody, no secondary antibody, 0.6%; (green line) no primary antibody, Anti-human kappa FITC secondary antibody at 0.2 µL, 1.0%.

Specifications

Product Data

• Clone Name: Abz518
• Applications: ELISA, FC, WB
• Recommended Dilution: WB: 1:2,000
  FC: 1:100
  ELISA: 1:10,000 to 1:100,000
• Reactivities: Human
• Isotype: IgG1
• Specificity: Humanized Recombinant HER2 Fab fragment was expressed in E. coli cells. The purity was estimated to be >90% by SDS-PAGE analysis.
• Formulation: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
• Concentration: 0.59 mg/ml - lot specific
• Conjugation: Unconjugated
• Storage: Store vial at 2-8° C. Dilute only prior to immediate use.
• Stability: Expiration date is six (6) months from date of receipt.
• Gene Name: erb-b2 receptor tyrosine kinase 2
• Database Link:
  Entrez Gene 2064 Human
  UniProt ID P04626
• Background: HER2 (human epidermal growth factor receptor 2) is a member of the epidermal growth factor receptor (HER/EGFR/ERBB) family. It is also called ERBB2, CD340 or proto-oncogene Neu. The protein is a receptor tyrosine kinase located on the plasma membrane of cells. Activation of the tyrosine kinase promotes cell proliferation and suppresses apoptosis. HER2 can dimerize with any other member of the ErbB family, which results in auto phosphorylation of tyrosine residues and activation of signal pathways. HER2 is over expressed in a significant proportion of cancer patients, resulting in an increased disease recurrence and poor prognosis. Therefore an early diagnosis of the HER2 status of the tumors is necessary to decide the appropriate treatment. Besides in breast cancer HER2 is over expressed in variety of different tumors. The over expression of HER2 makes it a target for immunotherapy of certain tumor patients. The antibody Trastuzumab (Herceptin) which recognizes HER2 was approved for the treatment of HER2 positive breast cancer patients in 1998. The original approval was for treatment of HER2 positive metastatic breast tumors. Later studies have shown that Herceptin is also beneficial for early stage HER2 positive tumor patients and it is approved as an adjuvant treatment. Additionally the antibody is now approved also for other HER2 positive tumors (metastatic gastric adenocarcinoma). This antibody is made from a humanized Fab fragment making it specific, efficient, and effective. Humanized Recombinant Anti-HER2 Fab fragment Antibody is useful for researchers interested in Cancer research.
• Synonyms: CD340, cluster of differentiation 340, ERBB2 (human), human epidermal growth factor receptor 2, HER2/neu, recombinant Monoclonal HER2, RabMAb HER2, Trastuzumab, Herceptin, Humanized Antibody, Recombinant Anti-HER2 Fab antibody, HER-2, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, p185erbB2
• Note: Humanized Recombinant Anti-HER2 Fab fragment Antibody has been tested for use in Flow Cytometry, Western Blot, and ELISA. This antibody recognizes structured HER2 and will work in western blot when the protein has not been denatured with DTT or bMe. Although not tested, this antibody could be useful in in IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user.